Клінічний досвід застосування агоністів гонадотропін-рилізинг-гормону у лікуванні лейоміоми матки із супутньою гінекологічною патологією

The objective: evaluation of the effectiveness of the use of GnRH agonists in the treatment of uterine fibroids on the background of combined gynecological pathology. Materials and methods. A comprehensive examination and treatment of 40 women aged 20–49 years with uterine myoma on the background of combined gynecological pathology (endometrial hyperplastic processes, endometriosis, infertility, diffuse fibrocystic mastopathy) were carried out. Patients were divided into two groups, 20 each. In the main group, women received buserelin acetate 3.75 mg in the form of a suspension for parenteral administration for 2–6 months. In the comparison group, 20 women were subjected to surgical treatment for similar indications, but they did not prescribe buserelin acetate before the operation. The observation period for women was 24 months. Results. After the use of buserelin acetate, a decrease in the severity of all clinical symptoms was noted in comparison with the initial data, the ultrasound and X-ray picture. When carrying out a comparative characteristic of the course of endoscopic operations, a decrease in the duration of conservative myomectomy and subtotal hysterectomy with a simultaneous decrease in intraoperative blood loss is evident. Conclusion. The use of GnRH agonists in the treatment of uterine leiomyoma on the background of combined gynecological pathology is highly effective and promising as an independent and complex method of therapy.